Einloggen

Thematische Bibliographien / Propranolol / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Propranolol.

Zeitschriftenartikel zum Thema „Propranolol“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Propranolol" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Kobeleva, Tatyana A., Alik I. Sichko, Marina I. Popova, and Elena M. Shapovalova. "Development and validation of a spectrophotometric method for the analysis of propranolol in a new soft dosage form "Propranozol"." Человек и его здоровье 24, no. 4 (2021): 83–90. http://dx.doi.org/10.21626/vestnik/2021-4/11.

Der volle Inhalt der Quelle

Annotation:

At present, the issue of creating and introducing into medical practice domestically produced drugs, the quality of man-ufacture of which is established using objective, highly sensitive optical physical and chemical methods, becomes relevant. Objective: to develop a spectrophotometric method for analysis of propranololol in the ointment "Propranozol" made on the basis of "Tizol" gel. Materials and methods. Pharmaceutical substance propranolol, gel "Tizol", soft dosage form "Propranosol" containing 0.5% of beta-adrenoblocker in titanium-containing base were used in the study. The analysis was

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Gajkiewicz, Magdalena, Radosław Zaucha, Julia Silldorff, et al. "Propranolol in treating various symptoms associated with autism spectrum disorder (ASD)." Quality in Sport 19 (August 17, 2024): 53778. http://dx.doi.org/10.12775/qs.2024.19.53778.

Der volle Inhalt der Quelle

Annotation:

Introduction and purpose This review provides an in-depth exploration of the pharmacology of propranolol, elucidating its mechanisms of action and clinical implications beyond its conventional indications, contextualizing propranolol’s role in ASD management. State of knowledge Propranolol is a non-cardioselective β-adrenergic receptor antagonist, commonly used among the population. Propranolol's mechanisms include reducing cardiac workload, vasoconstriction, and membrane stabilizing properties, which suggest its utility in managing anxiety. ASD, characterized by deficits in social interaction

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Li, Mi, and Yanqin Ji. "Propranolol Inhibits the Growth of Cervical Cancer Cells by Inhibiting Cyclic Guanosine Monophosphate/Protein Kinase G (cGMP/PKG) Pathway." Journal of Biomaterials and Tissue Engineering 12, no. 2 (2022): 422–26. http://dx.doi.org/10.1166/jbt.2022.2916.

Der volle Inhalt der Quelle

Annotation:

This study assesses the therapeutic effect of propranolol on cervical cancer and its mechanism. Propranolol’s effect on cervical cancer was evaluated by MTT, Western blotting, flow cytometry and colony formation. By searching Drug Bank and String, cGMP/PKG signaling might be downstream targets of propranolol for subsequent analysis. Our results found that propranolol could significantly inhibit Hela and SiHA cell vitality and clone formation in a dose dependent manner. Further, Annexin V-PE/7-AAD Apoptosis Detection assay showed that propranolol could increase Hela and SiHA cell apoptosis. Fin

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Sowinski, Kevin M., and Brad S. Burlew. "Impact of CYP2D6 Poor Metabolizer Phenotype on Propranolol Pharmacokinetics and Response." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17, no. 6 (1997): 1305–10. http://dx.doi.org/10.1002/j.1875-9114.1997.tb03097.x.

Der volle Inhalt der Quelle

Annotation:

We conducted an open‐label study to determine the impact of cytochrome P‐4502D6 (CYP2D6) on propranolol pharmacokinetics and response in 12 healthy men with CYP2D6 extensive metabolizer (EM) phenotype and 3 healthy men with CYP2D6 poor metabolizer (PM) phenotype. Subjects received R,S‐propranolol hydrochloride 80 mg every 8 hours for 16 doses. After the sixteenth dose, blood and urine samples were collected for 24 hours, and serum propranolol and urine metabolite concentrations were determined by chiral high‐performance liquid chromatography. Heart rate response to treadmill exercise was measu

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Hurley, Elisa A. "Pharmacotherapy to Blunt Memories of Sexual Violence: What's a Feminist to Think?" Hypatia 25, no. 3 (2010): 527–52. http://dx.doi.org/10.1111/j.1527-2001.2010.01108.x.

Der volle Inhalt der Quelle

Annotation:

It has recently been discovered that propranolol—a beta-blocker traditionally used to treat cardiac arrhythmias and hypertension—might disrupt the formation of the emotionally disturbing memories that typically occur in the wake of traumatic events and consequently prevent the onset of trauma-induced psychological injuries such as Post-traumatic Stress Disorder. One context in which the use of propranolol is generating interest in both the popular and scientific press is sexual violence. Nevertheless, feminists have so far not weighed in on propranolol. I suggest that the time is ripe for a ca

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Alotaibi, Hadil Faris, Haifa Alotaibi, Khaled M. Darwish, et al. "The Anti-Virulence Activities of the Antihypertensive Drug Propranolol in Light of Its Anti-Quorum Sensing Effects against Pseudomonas aeruginosa and Serratia marcescens." Biomedicines 11, no. 12 (2023): 3161. http://dx.doi.org/10.3390/biomedicines11123161.

Der volle Inhalt der Quelle

Annotation:

The development of bacterial resistance is an increasing global concern that requires discovering new antibacterial agents and strategies. Bacterial quorum sensing (QS) systems play important roles in controlling bacterial virulence, and their targeting could lead to diminishing bacterial pathogenesis. In this context, targeting QS systems without significant influence on bacterial growth is assumed as a promising strategy to overcome resistance development. This study aimed at evaluating the anti-QS and anti-virulence activities of the β-adrenoreceptor antagonist propranolol at sub-minimal in

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Kumar, Lalit, and Puneet Utreja. "Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization." Current Drug Therapy 15, no. 3 (2020): 238–48. http://dx.doi.org/10.2174/1574885514666190722164119.

Der volle Inhalt der Quelle

Annotation:

Background: Pharmaceutical scientists are exploring transdermal route for treatment of various systemic diseases nowadays. Transdermal nanocarrier systems show various advantages like bioavailability enhancement of drugs, avoidance of first pass hepatic metabolism, and reduction of dosing frequency of bioactive therapeutic molecules. Objective: The objective of the present research work was to encapsulate Propranolol hydrochloride into oleic acid vesicles and carry out in-vitro and in-vivo evaluation of oleic acid vesicular gel containing Propranolol hydrochloride. Method: Propranol hydrochlor

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Miguel-Puga, Adán, Gabriel Villafuerte, Mario Treviño, Emmanuel Ortega-Robles, and Oscar Arias-Carrión. "Effect of Propranolol on Motor Cortex Excitability in Essential Tremor: An Exploratory Study." Tremor and Other Hyperkinetic Movements 14 (January 2, 2024): 1. http://dx.doi.org/10.5334/tohm.829.

Der volle Inhalt der Quelle

Annotation:

Background: Essential tremor, the world’s most prevalent movement disorder, lacks a clear understanding of its pathophysiology. Propranolol, a non-specific beta-blocker capable of crossing the blood-brain barrier, is a primary choice for essential tremor treatment. While its tremor-reducing effects are generally attributed to peripheral actions, various uses hint at central adrenergic effects. Nevertheless, propranolol’s precise impact on the central nervous system in essential tremor subjects remains unexplored. Methods: In this study, we employed transcranial magnetic stimulation to assess t

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Gulzar, G. M., Showkat A. Zargar, M. S. Alai, et al. "Effect of acute administration of propranolol, carvedilol, iso-sorbide dinitrate, “propranolol plus iso-sorbide dinitrate” and “carvedilol plus iso-sorbide dinitrate” on portal venus pressure." JMS SKIMS 16, no. 2 (2013): 80–85. http://dx.doi.org/10.33883/jms.v16i2.215.

Der volle Inhalt der Quelle

Annotation:

Pharmacotherapy of portal hypertension in patients with cirrhosis includes beta-blockers, nitrates, somatastain analogues, alpha-blockers like prazocin. These drugs differ widely in their effectiveness, adverse effects and patient compliance. Beta-blockers particularly propranolol are the most commonly used drugs. Of late, carvedilol has been used and found to be superior to propranolol. The present study was aimed at assessing the effect of propranolol, carvedilol, iso-sorbide dinitrate; combination of “propranolol and iso-sorbide-dinitrate” and carvedilol and isosorbide dinitrate” on portal

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Rešić, Arnes, Zdenka Pleša Premilovac, Filip Jurić, and Marko Mesić. "Hipoglikemija – nuspojava terapije propranololom dojenačkih hemangioma – prikaz triju slučajeva." Paediatria Croatica 58, no. 4 (2014): 310–14. http://dx.doi.org/10.13112/pc.605.

Der volle Inhalt der Quelle

Annotation:

Peroralno primijenjen propranolol u dozi od 1-3 mg/kg/dan terapija je izbora kompliciranih hemangioma dojenačke dobi. Prikazujemo dva bolesnika s nastankom simptomatske hipoglikemije i jednog bolesnika s nastankom konvulzija najvjerojatnije povezanihs hipoglikemijom, koji su na peroralnoj terapiji propranololom radi liječenja dojenačkih hemangioma. Iako se propranolol priličnodugo primjenjuje u drugim indikacijama, i čini se pouzdanim lijekom, baš zbog svoje neselektivnosti u djelovanju potrebno je prepoznati moguće i rjeđe nuspojave kao što je hipoglikemija, posebice u novim indikacijama za p

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

&NA;. "Propranolol see Maprotiline/propranolol." Reactions Weekly &NA;, no. 341 (1991): 10. http://dx.doi.org/10.2165/00128415-199103410-00057.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Lucido, Christopher, W. Miskimins, and Paola Vermeer. "Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC." Cancers 10, no. 12 (2018): 476. http://dx.doi.org/10.3390/cancers10120476.

Der volle Inhalt der Quelle

Annotation:

Tumor cell metabolism differs from that of normal cells, conferring tumors with metabolic advantages but affording opportunities for therapeutic intervention. Accordingly, metabolism-targeting therapies have shown promise. However, drugs targeting singular metabolic pathways display limited efficacy, in part due to the tumor’s ability to compensate by using other metabolic pathways to meet energy and growth demands. Thus, it is critical to identify novel combinations of metabolism-targeting drugs to improve therapeutic efficacy in the face of compensatory cellular response mechanisms. Our lab

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

&NA;. "Propranolol see Butalbital/imipramine/propranolol." Reactions Weekly &NA;, no. 381 (1991): 10. http://dx.doi.org/10.2165/00128415-199103810-00050.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

&NA;. "Propranolol see Captopril/methyldopa/propranolol." Reactions Weekly &NA;, no. 305 (1990): 7. http://dx.doi.org/10.2165/00128415-199003050-00035.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Tchivileva, Inna E., Richard Ohrbach, Roger B. Fillingim, et al. "Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial." Cephalalgia 41, no. 7 (2021): 839–50. http://dx.doi.org/10.1177/0333102421989268.

Der volle Inhalt der Quelle

Annotation:

Introduction The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine. Methods In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9 weeks. The primary endpoint was change in a facial pain index derived from daily symptom diaries. Linear and logistic regression models tested for a migraine × treatment-group interaction in reducing facial pain index. Counterfactual models explored changes in headach

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Welle, S. L., K. S. Nair, and R. G. Campbell. "Failure of chronic beta-adrenergic blockade to inhibit overfeeding-induced thermogenesis in humans." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 256, no. 3 (1989): R653—R658. http://dx.doi.org/10.1152/ajpregu.1989.256.3.r653.

Der volle Inhalt der Quelle

Annotation:

The effect of the beta-adrenergic antagonist propranolol on the increase in resting metabolic rate (RMR) induced by overfeeding was examined to determine whether increased beta-adrenergic activity contributes to this response. Six male subjects who were overfed with carbohydrate (1,600 excess kcal/day) for 10 days without drug treatment (control group) had increases (compared with values after 10 days of weight maintenance) in RMR after 6 days [0.24 +/- 0.06 kcal/min (22%)] and 10 days of overfeeding [0.17 +/- 0.03 kcal/min (15%)]. Eight male subjects were given a weight-maintenance diet for 1

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1377 (2011): 32–33. http://dx.doi.org/10.2165/00128415-201113770-00112.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1384 (2012): 48. http://dx.doi.org/10.2165/00128415-201213840-00190.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1389 (2012): 36–37. http://dx.doi.org/10.2165/00128415-201213890-00132.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

&NA;. "Propranolol." Reactions Weekly &NA;, no. 759 (1999): 10. http://dx.doi.org/10.2165/00128415-199907590-00029.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1171 (2007): 23. http://dx.doi.org/10.2165/00128415-200711710-00062.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1121 (2006): 20–21. http://dx.doi.org/10.2165/00128415-200611210-00065.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1356 (2011): 31. http://dx.doi.org/10.2165/00128415-201113560-00106.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 34. http://dx.doi.org/10.2165/00128415-201113630-00136.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00137.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00140.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00141.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1364 (2011): 38. http://dx.doi.org/10.2165/00128415-201113640-00148.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1366 (2011): 25–26. http://dx.doi.org/10.2165/00128415-201113660-00094.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1367 (2011): 32. http://dx.doi.org/10.2165/00128415-201113670-00112.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

&NA;. "Propranolol." Reactions Weekly &NA;, no. 562 (1995): 10. http://dx.doi.org/10.2165/00128415-199505620-00038.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

&NA;. "Propranolol." Reactions Weekly &NA;, no. 428 (1992): 11. http://dx.doi.org/10.2165/00128415-199204280-00053.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

&NA;. "Propranolol." Reactions Weekly &NA;, no. 432 (1992): 15. http://dx.doi.org/10.2165/00128415-199204320-00083.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

&NA;. "Propranolol." Reactions Weekly &NA;, no. 457 (1993): 12. http://dx.doi.org/10.2165/00128415-199304570-00048.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

&NA;. "Propranolol." Reactions Weekly &NA;, no. 458 (1993): 10. http://dx.doi.org/10.2165/00128415-199304580-00049.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

&NA;. "Propranolol." Reactions Weekly &NA;, no. 683 (1998): 11–12. http://dx.doi.org/10.2165/00128415-199806830-00031.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1400 (2012): 35. http://dx.doi.org/10.2165/00128415-201214000-00133.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1402 (2012): 38–39. http://dx.doi.org/10.2165/00128415-201214020-00142.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1408 (2012): 27. http://dx.doi.org/10.2165/00128415-201214080-00094.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1409 (2012): 38. http://dx.doi.org/10.2165/00128415-201214090-00125.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1415 (2012): 41–42. http://dx.doi.org/10.2165/00128415-201214150-00149.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1415 (2012): 42. http://dx.doi.org/10.2165/00128415-201214150-00151.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1416 (2012): 37. http://dx.doi.org/10.2165/00128415-201214160-00122.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

&NA;. "Propranolol." Reactions Weekly &NA;, no. 372 (1991): 8. http://dx.doi.org/10.2165/00128415-199103720-00044.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

&NA;. "Propranolol." Reactions Weekly &NA;, no. 403 (1992): 7. http://dx.doi.org/10.2165/00128415-199204030-00023.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

&NA;. "Propranolol." Reactions Weekly &NA;, no. 417 (1992): 10. http://dx.doi.org/10.2165/00128415-199204170-00041.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1111 (2006): 19. http://dx.doi.org/10.2165/00128415-200611110-00058.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1114 (2006): 16–17. http://dx.doi.org/10.2165/00128415-200611140-00047.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

&NA;. "Propranolol." Reactions Weekly &NA;, no. 924 (2002): 10. http://dx.doi.org/10.2165/00128415-200209240-00026.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1280 (2009): 39. http://dx.doi.org/10.2165/00128415-200912800-00133.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!